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Many phytochemicals exert activities as agonists of peroxisome proliferator-activated
receptor gamma (PPARγ). This study aims to investigate whether phytochemicals are
agonists of the PPARγ/RXRα pathway and modulate the target gene OCTN2. In this
study, a luciferase reporter gene system was used to screen novel OCTN2 activators
from 39 phytochemicals. Kaempferol, curcumin, and puerarin were found to show the
significant PPRE-mediated luciferase activities (>150%) at 20 µM and showed a dose-
dependent manner. Phytochemicals also elevated the mRNA and protein expression of
OCTN2 in a dose-dependent fashion in colorectal cancer SW480 cells. These induction
effects were gradually inhibited by PPARγ antagonist GW9662 in the luciferase reporter
gene system and in SW480 cells. Moreover, the results of cell viability assay imply
that three phytochemicals probably induce OCTN2 expression leading to the enhanced
uptake of its substrate, oxaliplatin, thereby making cells more sensitive to oxaliplatin. The
molecular docking study showed the possible binding sites of phytochemicals in PPARγ
protein, and all of the docked phytochemicals fitted the same active pocket in PPARγ
as troglitazone. All three phytochemicals exhibited hydrogen bonds between their polar
moieties and the amino acid residues. Thus, we identified three phytochemicals as
PPARγ ligands, which potentiated the expression and activity of OCTN2.
Keywords: phytochemicals, OCTN2, PPARγ, RXRα, activator
INTRODUCTION
Phytochemicals are derived from plants and play an essential role in long-term health and offer
chemical scaffolds for discovering novel drugs against a wide range of therapeutic targets (Ernst,
2003). Many phytochemicals govern the expression of drug-metabolizing enzymes and drug
transporters through activating several nuclear receptors (NRs) and binding to the responsive
elements within those genes.
The peroxisome proliferator-activated receptor (PPAR) family consists of three subtypes,
namely PPAR alpha, beta and gamma, which are encoded by three distinct genes. Ligand-activated
PPARγ acts as a transcription factor and assembles into a heterodimer complex with retinoid
X receptor alpha (RXRα) or retinoic acid receptor alpha (RARα), binding to the peroxisome
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proliferator responsive element (PPRE) within the promoter
of target genes. Trans-activation could regulate adipocyte
proliferation and differentiation (CCAAT/enhancer binding
protein alpha, signal transducer and activator of transcription 1),
lipid metabolism (GABA receptor modulator, lipoprotein lipase),
glucose homeostasis (glucose transporter type 4, c-Cbl-associated
protein, insulin receptor substrates 1 and 2) as well as insulin
sensitization (tumor necrosis factor-α, leptin, adiponectin; Ricote
et al., 1998; Evans et al., 2004; Zoete et al., 2007). Two groups of
PPARγ agonists have been reported: one is the synthetic agonists
including thiazolidinediones (TZDs; Quinn et al., 2008); the other
is the natural agonists such as endogenous ligands and naturally
occurring compounds (Belvisi and Hele, 2008). The development
of novel and effective PPARγ agonists from naturally occurring
compounds with an improved safety profile and fewer side effects
is of great interest.
Organic anion/cation transporter 2 (OCTN2) is a member
of the solute carrier transporters, which are expressed in
human tissues including the kidney, heart, brain, skeletal
muscle, small and large intestine, etc. (Tamai et al., 1998; Wu
et al., 1998; Peltekova et al., 2004). It has been shown to
transport various endogenous substrates (carnitine and choline),
as well as various xenobiotics (cimetidine, mildronate, verapamil,
pyrilamine, oxaliplatin, imatinib, and cephaloridine; Grigat et al.,
2009; Kano et al., 2009; Kato et al., 2009; Jong et al., 2011;
Angelini et al., 2013). The occurrence of mutations in OCTN2
resulted in systemic carnitine deficiency and an early lethality
attributed to metabolic abnormalities in the cardiovascular
system and skeletal muscle (Scaglia et al., 1998). It was reported
that the heterodimer of PPARγ/RXRα could trigger human
OCTN2 expression by binding to the PPRE in the first intron,
especially under the effect of troglitazone, which is a conventional
ligand of PPARγ (D’Argenio et al., 2010). We speculate that
the activation of PPARγ by a natural agonist can trigger the
expression of OCTN2, which is the PPARγ target gene. In our
previous study, luteolin, an agonist of PPARγ, could transactivate
OCTN2, thereby increasing the transport of oxaliplatin (Qu et al.,
2014).
In this study, based on the mechanism of PPARγ-activating
OCTN2 expression, we constructed a luciferase reporter
gene system for screening novel OCTN2 activators from
phytochemicals. The novel PPARγ agonists from herbal
compounds supply the basically pharmacological structure
which is beneficial for developing more effective ligands. These
phytochemicals are also helpful for those patients with OCTN2
deficiency disease or for facilitating the uptake of OCTN2
substrates.
MATERIALS AND METHODS
Chemicals and Reagents
GW9662, troglitazone, oxaliplatin and 39 phytochemicals were
purchased from Sigma-Aldrich (St. Louis, MO, USA) and the
National Institutes for Food and Drug Control (Beijing, China).
TRIzol reagent was obtained from Takara (Dalian, China).
Lipofectamine 2000 was obtained from Invitrogen (Carlsbad, CA,
USA). All of the primary antibodies were purchased from Abcam
Labs (Cambridge, MA, USA).
Molecular Clones
The expression plasmids of pcDNA3.1-PPARγ and RXRα were
constructed. The core sequence of the PPARγ response element
(PPRE, AGGTGAAAGGGCA) identified in the first intron of
OCTN2 was utilized to construct an oligonucleotide (D’Argenio
et al., 2010). A pair of complementary oligonucleotides
containing OCTN2 PPRE and flanking sites for Kpn I and
Hind III were annealed and subcloned into the pGL4.23 (luc2)
vector digested by Kpn I and Hind III (Promega, Madison, WI,
USA), which contains the minimal promoter (minP) followed by
the luciferase reporter gene luc2 (Promega, Madison, WI, USA;
D’Argenio et al., 2010).
Cell Culture
COS-7 and SW480 cell lines were obtained from the American
Type Culture Collection (ATCC, USA). Cells were grown in
DMEM containing L-glutamine supplemented with penicillin
(100 U/ml), streptomycin (100 g/ml) and 10% (v/v) fetal
bovine serum (FBS) at 37◦C in a humidified atmosphere with
5% CO2.
Transfection and Dual-luciferase
Reporter Assay
COS-7 cells were cultured in a 24-well plate at a density
of 1 × 105/well at 37◦C. After 8 h, COS-7 cells were co-
transfected with pcDNA3.1-PPARγ and RXRα (0.2 µg/well),
pGL4.23-PPRE/OCTN2 (0.2 µg/well) or pGL4.23 (0.2 µg/well),
as well as pRL-TK (0.02 µg/well) using Lipofectamine 2000 in
accordance with the manufacturer’s instructions. In an initial
screening assay, cells were washed by PBS and exposed to
phytochemicals at 20 µM for 48 h. DMEM medium containing
phytochemicals or DMSO was renewed every 24 h. In the
dose-dependent assay, transfected cells were exposed to either
phytochemicals or troglitazone at various concentrations (1, 2.5,
5, 10, 20, or 40 µM) for 48 h. After being washed twice by
PBS, treated cells were harvested and lysed. Then, 20 µl of
supernatant was aspirated and used for dual-luciferase activity
detection. The luciferase activity is represented as relative light
units (RLUs).
Cell Treatment, RNA Extraction, and
Quantitative RT-PCR
SW480 cells were seeded in a 6-well plate at a density of
5 × 105 cells/well and exposed to potent activators from
phytochemicals at various concentrations (0, 5, 10, 20, or 40 µM)
for 48 h at 37◦C. Only DMSO (v/v 0.1%) was added to control
cells. DMEM medium containing phytochemicals or DMSO
was renewed every 24 h. In the antagonist assay, 20 µM
phytochemicals plus a range of concentrations of GW9662 (5,
10, or 20 µM) was incubated with SW480 cells for 48 h. Cells
were washed twice by PBS, and total mRNA was extracted by
TRIzol reagent (Takara). Two micrograms total RNA was reverse
transcribed to cDNA following the manufacturer’s instructions
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of the first strand cDNA synthesis kit (Takara). The level of
OCTN2 mRNA was determined by quantitative RT-PCR using
a SYBR Green Kit (Bio-Rad, Hercules, CA, USA). The primers
were the following: OCTN2, F: 5′-CCATTGTGACCGAGTGGA
ACC-3′, R: 5′-ACATTCTTCCGGCCAAACCTG-3′ and β-actin,
F: 5′-TTGCCGACAGGATGCAGAAGGA-3′, R: 5′-AGGTG
GACAGCGAGGCCAGGAT-3′. The PCR conditions included
the following steps: initial denaturation at 95◦C for 2 min,
followed by 40 cycles at 95◦C for 15 s, 60◦C for 15 s, and 72◦C
for 30 s. The relative mRNA levels of OCTN2 were normalized
to β-actin and quantitated by the 2−11Ct method (Livak and
Schmittgen, 2001).
Western Blotting
After treatment with three phytochemicals, SW480 cells were
lysed, and total proteins were extracted. Concentrations of
proteins were determined by the BCA assay (Thermo Scientific,
Rockford, IL, USA). Western blotting and the calculation of the
relative protein level of OCTN2 were conducted as described in
our previous study (Qu et al., 2014).
Cell Viability
SW480 cells were grown in 6-well plates and treated with
either 20 µM phytochemicals or DMSO (v/v 0.1%) for 48 h.
DMEM medium containing phytochemicals or DMSO was
renewed every 24 h. Cells were washed with PBS and seeded
in 96-well plates (2 × 104/well) and then exposed to various
concentrations of oxaliplatin for 48 h at 37◦C. Next, 20 µl of
MTS (tetrazolium salt, Promega) was added to each well, followed
by 2 h of incubation at 37◦C. The absorbance was analyzed
using a Microplate Reader FLX800 at 490 nm (Biotek). The
IC50 value was calculated by SPSS version 13.0 (Chicago, IL,
USA).
Autodock Analysis
To investigate the possible binding sites of phytochemicals
in PPARγ protein, the molecular docking analysis was
conducted by Autodock Tools (ADTs) v1.1 and the Autodock
v4.0.5 program, including Autogrid and Autodock software
(Copyright_1991e2000, the Scripps Research Institute1). The
co-crystalized structure of PPARγ (PBD ID: 2PRG) was obtained
from the RCSB Protein Data Bank (PBD), and 3D structures of
the three phytochemicals were downloaded from the PubChem
website. The rigid roots of each phytochemical were defined
automatically, and the amide bonds were made non-rotatable by
ADT. The active site of PPARγ was considered a rigid molecule,
whereas the phytochemicals were treated as being flexible. The
internal default parameters in the AutoDock software were
used to analyze all of the variables, except for the number of
docking runs (10), the medium number of energy evaluations
on genetic algorithm eGA (2, 500,000) and the maximum
number of generations in GA (5000). Following the completion
of the docking search, the final compound pose was located
by evaluating AutoDock’s empirical scoring function in which
the conformation with the lowest docked energy value was
1http://www.scripps.edu/mb/olson/doc/autodock
chosen as the best. The docking model and hydrogen bonds
were predicted by ADT and Pymol software (DeLano Scientific
LLC).
Statistical Analysis
Values are presented as the mean± SD. Statistical comparisons of
data were performed with one-way analysis of variance (ANOVA)
followed by a post hoc test using SPSS 13.0 (Chicago, IL, USA).
p-values less than 0.05 (p < 0.05) were considered statistically
significant.
RESULTS
Construction of the
PPRE/OCTN2-Luciferase Reporter Gene
Assay
We successfully constructed the pGL4.23-OCTN2/PPRE
plasmid containing the PPRE of OCTN2, min Promoter
and luc2 gene (Figure 1A). We transiently transfected the
constructs or pGL4.23 into COS-7 cells with co-transfection of
either pcDNA3.1-PPARγ/RXRα or empty vector (pcDNA3.1).
In cells transiently transfected with pGL4.23-OCTN2/PPRE
and PPARγ/RXRα, the luciferase activity increased 3.9-
fold (p < 0.05) and 11-fold (p < 0.05), respectively,
which was stimulated by troglitazone compared to cells
transfected with pGL4.23 without transfection of PPARγ/RXRα
(Figure 1B). To detect whether endogenous PPARγ interferes
with luciferase activity, only pGL4.23-OCTN2/PPRE was
transfected in COS-7 cells with or without exposure to
troglitazone. However, troglitazone did not significantly increase
luciferase activity through activated endogenous PPARγ
(Figure 1B).
After transfection with pGL4.23-OCTN2/PPRE and
pcDNA3.1-PPARγ/RXRα, COS-7 cells were exposed to
troglitazone for 48 h. In Figure 1C, troglitazone increased
PPRE-luciferase activity in a dose-dependent manner, indicating
that it modulated OCTN2 expression. Moreover, to test
antagonist activity, transfected cells were exposed to increasing
concentrations of GW9662 in the presence of 20µM troglitazone.
The luciferase induction by 20 µM troglitazone was abrogated
by GW9662 in a concentration-dependent manner (p < 0.01;
Figure 1D).
Induction Profile of Phytochemicals on
PPRE/OCTN2-Luciferase Activity
Based on the PPRE/OCTN2-luciferase reporter system, the
induction effects of 39 phytochemicals on OCTN2 were
investigated at 20 µM. DMSO solution (0.1% v/v) acted
as the control (this luciferase activity was considered to be
onefold activation), and the results are summarized in Figure 2
and Table 1. Of these compounds evaluated for PPARγ
transactivation activity, only three phytochemicals, namely
kaempferol, curcumin and puerarin, had a significant inducible
effect that was more than a 150% increase compared to the
control group. These findings imply that the potent PPARγ
Frontiers in Pharmacology | www.frontiersin.org 3 June 2016 | Volume 7 | Article 189
fphar-07-00189 June 26, 2016 Time: 11:51 # 4
Luo et al. Phytochemicals Mediates OCTN2
FIGURE 1 | Construction of PPRE/OCTN2-luciferase reporter gene assay. (A) The structure of the pGL4.23-OCTN2/PPRE plasmid containing the PPRE of
OCTN2, mini promoter and luc2 gene. (B) Identification of Luciferase reporter gene assay. + indicates the transfection of plasmid or the addition of drugs. The
relative luciferase units (RLUs) were determined as described in Section “Materials and Methods” indicates untransfected or without addition of drug. ∗p < 0.05 vs.
Group 1; #p < 0.05 vs. Group 5. (C) Troglitazone (Trog) increased PPRE-luciferase activities in a dose-dependent manner. Data are relative values to the
DMSO-treated group. ∗p < 0.05, ∗∗p < 0.01 vs. the DMSO-treated group. (D) GW9662 inhibited PPRE-luciferase activities induced by troglitazone. ∗p < 0.05,
∗∗p < 0.01 vs. the 20 µM troglitazone alone without GW9662 group. All values are mean ± SD of three separate experiments.
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FIGURE 2 | Effects of phytochemicals and antagonists on PPRE luciferase activities. (A) The structure of kaempferol, curcumin, and puerarin. (B) Effects of
three phytochemicals on PPRE/OCTN2-mediated luciferase activities. Control is 0.1% DMSO. ∗p < 0.05, ∗∗p < 0.01 vs. Control group. (C) GW9662 antagonized
phytochemical-induced luciferase activities. ∗p < 0.05, ∗∗p < 0.01 vs. the 20 µM phytochemicals alone group.
activators might activate PPARγ and consequently induce the
expression of OCTN2.
Concentration-Dependent Effects of
Phytochemicals on
PPRE/OCTN2-Mediated Luciferase
Expression
Three phytochemicals at various concentrations were used to
determine their dose-dependent effects. In Figure 2, we observed
that the PPRE-mediated luciferase activity was gradually
enhanced in accordance with the increase in phytochemical
dose and reached the most induction during exposure of
transfected cells to these phytochemicals at 20 and 40 µM
(p < 0.05). To determine whether the induction effects of potent
ligands on OCTN2 were dependent on PPARγ, the antagonist
GW9662 was used to co-incubate with phytochemicals and
transfected cells. As illustrated in Figure 2, phytochemical-
induced luciferase activities were gradually inhibited by GW9662
in a concentration-dependent manner. GW9662 (20 µM)
completely abrogated the induction effects of the phytochemical.
Effects of Phytochemicals on mRNA and
Protein Levels of OCTN2 in Colon Cancer
SW480 Cells
To provide better insight into OCTN2 expression induced by
phytochemicals in cells, three phytochemicals were incubated
with SW480 cells at various concentrations (5–40 µM). As shown
in Figure 3, compared to the control group (0.1% DMSO), the
three phytochemicals significantly induced OCTN2 mRNA and
protein levels in a dose-dependent manner.
Antagonist GW9662 Blocks the Induction
of OCTN2 Expression by Phytochemicals
in SW480 Cells
To determine whether the induction effects of potent ligands on
OCTN2 expression were dependent on PPARγ in SW480 cells, a
series of concentrations of GW9662 was used to co-incubate with
20 µM phytochemicals and SW480 cells. In Figure 4, the relative
expression of OCTN2 protein was decreased with the increase in
GW9662. The expression of OCTN2 decreased to 0.4- and 0.6-
fold of the control group at 10 and 20 µM (p< 0.05).
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TABLE 1 | Induction profile of phytochemicals on PPRE/OCTN2-Luciferase activity.
Phytochemical name Relative RFU fold change (% of blank) Phytochemical name Relative RFU change (% of blank)
Troglitazone 188.34 ± 14.85 Ginkgolide A 112.26 ± 12.80
Blank (DMSO) 100.00 ± 8.05 Salidroside 111.98 ± 12.40
Kaempferol 189.89 ± 5.98 Silymarin 109.18 ± 16.55
Curcumin 179.71 ± 13.81 Breviscapine 108.73 ± 19.10
Puerarin 153.04 ± 12.88 Aloe-emodin 105.30 ± 18.72
Salvianolic acid B 143.54 ± 6.01 Echinacoside 104.93 ± 16.62
Isocorynoxeine 138.24 ± 27.39 Ginkgolide C 104.14 ± 9.67
Ursolic acid 133.81 ± 8.23 Ophiopogonin 102.64 ± 12.58
Rutin 131.78 ± 26.51 Protopanaxatriol 98.19 ± 3.54
Daidzin 131.27 ± 44.63 Corynoxeine 97.44 ± 20.92
Polydatin 128.54 ± 57.91 Laburnine 94.35 ± 14.43
Ginsenoside 127.94 ± 29.03 Resveratrol 93.70 ± 4.37
Matrine 122.14 ± 3.05 Quercitrin 81.78 ± 6.36
Hesperidin 119.71 ± 17.87 Ferulic acid 80.27 ± 17.08
Rheinic acid 119.34 ± 30.34 Hyperoside 75.26 ± 4.35
Protopanaxatriol 118.63 ± 1.96 Tanshinone IIA 73.30 ± 22.98
hydroxysafflor yellow A 115.91 ± 24.49 Geniposide 71.67 ± 11.39
Ginsenoside Rc 114.15 ± 25.25 Nobiletin 67.54 ± 13.50
Ginkgolide B 113.45 ± 13.75 Osthole 66.99 ± 30.08
Oleanolic acid 113.41 ± 5.65 Berberine hydrochloride 46.28 ± 27.01
Engelitin 112.53 ± 11.77
Impact of OCTN2 Induction by
Phytochemicals on Oxaliplatin
Cytotoxicity to SW480 Cells
To determine whether phytochemicals make oxaliplatin
more cytotoxic to cells by inducing OCTN2 expression and
enhancing oxaliplatin uptake, SW480 cells pretreated with the
three phytochemicals were exposed to oxaliplatin at various
concentrations for 48 h. Cell viability was determined by the
MTS assay, and IC50 values were calculated. In Figure 5, IC50
values of cells pretreated by kaempferol, curcumin and puerarin
decreased to 0.7-, 0.75-, and 0.77-fold of the group of oxaliplatin
alone (p< 0.05).
Molecular Docking Analysis
As illustrated in Figure 6, although, the Kd values of docking
parameter for kaempferol, curcumin, and puerarin (2.38, 1.21,
and 1.29 µM) were lower than that of troglitazone (6.37 nM),
all three docked phytochemicals fitted the same active pocket in
PPARγ as troglitazone, including amino acids Phe226, Cys285,
Arg288, Ser289, Ala292, Glu295, Ile296, His323, Ile326, Tyr327,
Met329, Leu330, Leu333, Phe363, Met364, His449, and Tye473.
All of them exhibited hydrogen bonds between their polar
moieties and the amino acid residues. The 4′-OH substituent
of kaempferol formed a hydrogen bond with Arg288, while the
7-OH afforded the second hydrogen bond with the Tyr473 or
His323 residue of PPARγ. Curcumin made five potent hydrogen
bonds with the chain of the Arg288, Glu343, Leu228, and Tyr327
residues through 3′-OH, 4′-OH, and 4′-OH. Puerarin also made
five important hydrophobic interactions with Arg280, Arg288,
Glu343, and Ser342 through 4′-OH, 4′′-OH, and 7-OH.
DISCUSSION
Currently, many studies have considered cell-based
transactivation or ligand binding assays to screen for agonists
by assessing the transcriptional activity of PPARγ in vitro.
In our study, we developed a simple screening cell model to
identify OCTN2 activators based on a PPRE-luciferase cell model
using activation of the PPARγ/RXRα pathway. In the transient
transfection, the expression vector of PPARγ/RXRα and the
pGL4.23 (luc2) vector, which contains the minimal promoter
(minP) and PPRE of OCTN2 followed by the luciferase reporter
gene luc2, were transfected in COS-7 cells. The cell model is
applicable for generating and evaluating new ligands of PPARγ.
Their advantages are ease of use, efficiency and reproducibility,
which make the luciferase reporter gene assay the most common
method for evaluating PPARγ activation. Additionally, this
method is beneficial for structure-activity studies and guiding
chemical analyses. All phytochemicals are common food and
plant sources, and possess different chemical scaffold diversities.
In supplementary file 1, we set up the parameters for the
screening model as follows: the reading time of 10 s, the seeded
cell number of 105 cells/well, the treatment time of 48 h. Based
on this model, three phytochemicals have been screened as
potent activators of OCTN2. In supplementary file 2, the results
of cell viability showed the maximum non-toxic concentration
of three natural compounds was 33 µM toward the COS-7 and
SW480 cells (>90%). In the subsequent cell experiments, the
concentration did not exceed 40 µM.
Mounting evidence suggests that the increase of PPARγ
expression and its transcriptional activity as a target play an
important role of anti-inflammation and the suppression of
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FIGURE 3 | Effects of phytochemicals on mRNA and protein levels of OCTN2 in colon cancer SW480 cells. The quantitation and calculation of relative
expression of OCTN2 mRNA (A) and protein (B) were performed as described in Section “Materials and Methods.” The vehicle control was 0.1% DMSO. ∗p < 0.05
vs. the vehicle control group.
inflammation-driven colon cancer (Koeﬄer, 2003; Voutsadakis,
2007). Many naturally occurring elicit their chemopreventive
actions against inflammation-induced colorectal cancer through
PPARγ activation (Carter et al., 2009). Due to the high expression
level of PPARγ, the colon cancer cell SW480 was selected as a tool
cell line to further investigate the effect of three phytochemical
on the trans-activation of PPARγ and the regulation of OCTN2,
as described in our published study (Qu et al., 2014). To
detect the transport activity induced by three phytochemicals,
oxaliplatin, an excellent substrate of OCTN2, was used in the
cell viability assay, which was identified in previous studies
(Jong et al., 2011; Qu et al., 2014). Except the cell model,
the structure-based docking analysis in silico also provide a
approach for aiding the performance of the contaction of ligand
and PPARγ (Encinar et al., 2015). Although, the Kd values of
docking parameter for kaempferol, curcumin and puerarin were
lower than that of troglitazone, all three docked phytochemicals
fitted the same active pocket in PPARγ as troglitazone. These
phytochemicals supply the chemical scaffold diversities, and will
be new drug leads toward PPARγ. Kaempferol is a flavonoid and
is abundant in tea, broccoli, delphinium, witch-hazel, grapefruit,
cabbage, kale, beans, endive, leek, tomato, strawberries, grapes,
brussel sprouts, apples, and other plant sources (Calderon-
Montano et al., 2011; Chen and Chen, 2013). Competitive
ligand-binding assays confirmed that kaempferol competed
with rosiglitazone at the same binding pocket site as PPARγ
(IC50 = 23.1, 30 or 49.9 µM; Fang et al., 2008; Zoechling
et al., 2011; Jungbauer and Medjakovic, 2012). Kaempferol
could significantly improve insulin-stimulated glucose uptake
in mature 3T3-L1 adipocytes through PPARγ activation (Lee
et al., 2015). Moreover, kaempferol acted as a PPARγ agonist
and significantly stimulated PPARγ-induced luciferase activities
in a dose-dependent manner in a transient reporter assay
(Liang et al., 2001; Fang et al., 2008), which is consistent with
our results. To predict the binding mode of kaempferol in
PPARγ, the autodock results showed that kaempferol fitted the
same active pocket as the positive agonist troglitazone through
the formation of hydrogen bonds between polar moieties and
amino acid residues. The 4′-OH and 7-OH substituents of
kaempferol formed a hydrogen bond with Arg288, Tyr473, or
His323 residues of PPARγ. A further antagonist assay showed
that GW9662 apparently inhibited kaempferol-induced luciferase
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FIGURE 4 | GW9662 at various concentrations antagonized natural activator-induced protein expression of OCTN2 in SW480 cells. ∗p < 0.05,
∗∗p < 0.01 vs. the 20 µM phytochemicals alone group.
activities. In SW480 cells, the PPARγ target gene OCTN2 was
elevated by kaempferol at both the mRNA and protein levels in
a dose-dependent fashion. These findings imply that kaempferol
is a PPARγ agonist and modulates expression of the target
gene OCTN2. Cell viability induced by oxaliplatin represents
the uptake ability of OCTN2 (Jong et al., 2011). In our study,
we also found that pretreatment with kaempferol contributed
to higher inhibition of cell growth induced by oxaliplatin,
compared to the oxaliplatin alone group. Numerous reports have
shown that the consumption of kaempferol, some glycosides
of kaempferol and several kaempferol-containing foods may
be beneficial in reducing the risk of developing some types of
cancer and cardiovascular diseases (Garcia-Closas et al., 1998;
Gates et al., 2007; Nothlings et al., 2007; Cui et al., 2008).
Evidence suggests that kaempferol is used in combination with
some chemotherapeutic drugs and facilitates their cytotoxicity,
such as cisplatin (Luo et al., 2010), 5-fluorouracil (Zhang et al.,
2008), cytarabine (Nadova et al., 2007), doxorubicin (Sharma
et al., 2007), mitoxantrone and the active metabolite of irinotecan
(SN-38; Imai et al., 2004). The pharmacokinetic studies of
kaempferol in rats found that intravenous administration of
25 mg/kg kaempferol or oral administration of resulted in serum
levels of 4.99 and 1.74 µM (Zhang et al., 2015; Qian et al.,
2016). Pretreatment of SW480 cells with kaempferol provides
new insight into the sensitizing of cancer cells to the cytotoxic
effects of oxaliplatin, thereby leading to improved oxaliplatin
therapeutic effects or decreased toxicity.
Curcumin, a polyphenol obtained from the turmeric plant,
Curcuma longa, has received attention as a promising dietary
supplement based on its various biological effects such as
anti-oxidant, anti-inflammatory, and anti-tumor properties
(Srivastava et al., 1995; Maheshwari et al., 2006). Curcumin
may act synergistically with the oxaliplatin in gastric cancer
by inducing apoptosis via Bcl/Bax-caspases pathways (Zhou
et al., 2016). Curcumin also mediates CXC-Chemokine/NF-κB
signaling pathway and reverses oxaliplatin-acquired resistance
in colorectal cancer cell lines (Ruiz de Porras et al., 2016).
In our study, curcumin may only activate PPARγ at high
doses (above 20 µM) in a luciferase reporter assay but could
elevate the protein and mRNA levels of PPARγ and OCTN2
in a dose-dependent manner in SW480 cells, even at lower
doses (5 and 10 µM). However, curcumin has been reported
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FIGURE 5 | Influence of the pretreatment of 20 µM phytochemicals on cell viability of SW480 cells against oxaliplatin. ∗p < 0.05 vs. the oxaliplatin alone
group.
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FIGURE 6 | Docking poses and activity pocket for troglitazone and three phytochemicals in PPARγ protein (PDB ID: 2PRG). (A) Docking site and (B)
important residues are labeled and shown as sticks to facilitate the localization of these poses on the active site region in PPARγ. (C) The compounds form hydrogen
bonds (red dot) with key residues.
to activate PPARγ (Kuroda et al., 2005; Nishiyama et al., 2005),
and it is controversial whether this activation reflects curcumin
directly binding to the receptor or is mediated through the
effects of receptor expression or levels of the endogenous
ligand 15d-PGJ2 (Zhang et al., 2006; Narala et al., 2009). More
studies are needed to clarify whether curcumin increases PPARγ
activity through multiple pathways induced by curcumin. The
pharmacokinetic studies of curcumin in humans found that oral
administration of 8 g/day curcumin resulted in serum levels of
1.75 µM (Cheng et al., 2001). Pharmacokinetic studies of herb
products containing curcumin in long-term use will be helpful to
determine the maximum concentration of curcumin in the serum
and whether it activates PPARγ and induces OCTN2 expression.
Further autodocking results also showed that curcumin fitted the
active pocket in PPARγ and made five potent hydrogen bonds
with the chain of Arg288, Glu343, Leu228, and Tyr327 residues.
Puerarin is a type of isoflavone and is the main active
phytochemical of kudzu root, which has strong potential in the
Frontiers in Pharmacology | www.frontiersin.org 10 June 2016 | Volume 7 | Article 189
fphar-07-00189 June 26, 2016 Time: 11:51 # 11
Luo et al. Phytochemicals Mediates OCTN2
treatment of various diseases such as cardiovascular disease,
hepatitis, insulin resistance, etc. (Xing et al., 2011; Chen et al.,
2012; Guo et al., 2013). Pharmacokinetic studies were conducted
in male rats received puerarin (200 mg/kg, po) and the plasma
concentrations (Cmax) reached 2.47µM (Su et al., 2016). Puerarin
may act as a chemopreventive and/or chemotherapeutic agent
in colon cancer cells HT-29 and hepatocellular carcinoma cell
SMMC-7721 by reducing cell viability and inducing apoptosis
through bcl-2/caspase3 or mitochondria-dependent pathway (Yu
and Li, 2006; Zhang et al., 2014). Although, the direct activation
of PPARγ by puerarin has not been found in previous research,
many reports found that puerarin promoted PPARγ and target
gene expression (Zhao and Zhou, 2012; Guo et al., 2013).
Our studies showed that puerarin activated the PPARγ/RXRα
pathway and elevated the expression of its target gene OCTN2.
Puerarin affected the transport efficiency of OCTN2 toward
oxaliplatin through activation of the PPARγ/RXRα pathway and
transduction of OCTN2. Puerarin also made five important
hydrophobic interactions with Arg280, Arg288, Glu343, and
Ser342 through 3′-OH, 4′-OH, and 4′′-OH.
Epidemiological and pre-clinical data suggest that kaempferol,
curcumin, and purarin may regulate multiple signaling
pathways involved in cancer cell proliferation and apoptosis
in vitro and vivo (Kotecha et al., 2016). In our study, these
phytochemicals acted as a sensitizer through the alteration of
the pharmacokinetic of oxaliplatin in cancer cells. However,
due to the less pharmacokinetic studies in human, whether
the plasm concentration of phytochemicals could sufficiently
trigger PPARγ/OCTN2 pathway in vivo is still not clear. Future
pharmacokinetic studies of these phytochemicals in vivo will be
useful for determining a suitable dose range that will effectively
induce OCTN2 expression as well as enhance oxaliplatin effect
with less toxicity in other normal tissues.
CONCLUSION
We constructed a luciferase reporter gene system for
screening novel OCTN2 activators from phytochemicals.
Three phytochemicals, namely kaempferol, curcumin
and puerarin, were selected, and further biological
activity experiments and binding model analyses
elucidated that these phytochemicals appeared to mediate
OCTN2 expression and activity through PPARγ/RXRα
activation.
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